Project

ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)

Automatically Closed · 2022 until 2024

Jörger Markus, Wittwer Yvonne, Quinter Janine